The Bezafibrate Infarction Prevention (BIP) study and accompanying large registry have been previously described. 16, 17 Briefly, the BIP trial Background-The independent association between elevated triglycerides and all-cause mortality among patients with established coronary heart disease is controversial. The aim of this study was to investigate this association in a large cohort of patients with proven coronary heart disease. Methods and Results-The study cohort comprised 15 355 patients who were screened for the Bezafibrate Infarction Prevention (BIP) trial. Twenty-two-year mortality data were obtained from the national registry. Patients were divided into 5 groups according to strata of fasting serum triglycerides: (1) low-normal triglycerides (<100 mg/dL); (2) highnormal triglycerides (100-149 mg/dL); (3) borderline hypertriglyceridemia triglycerides (150-199 mg/dL); (4) moderate hypertriglyceridemia triglycerides (200-499 mg/dL); (5) severe hypertriglyceridemia triglycerides (≥500 mg/dL). Ageand sex-adjusted survival was 41% in the low-normal triglycerides group than 37%, 36%, 35%, and 25% in groups with progressively higher triglycerides (P<0.001). In an adjusted Cox-regression for various covariates including high-density lipoprotein cholesterol, each 1 unit of natural logarithm (Ln) triglycerides elevation was associated with a corresponding 6% (P=0.016) increased risk of 22-year all-cause mortality. The 22-year mortality risk for patients with severe hypertriglyceridemia was increased by 68% when compared with patients with low-normal triglycerides (P<0.001). Conclusions-In patients with established coronary heart disease, higher triglycerides levels are independently associated with increased 22-year mortality. Even in patients with triglycerides of 100 to 149 mg/dL, the elevated risk for death could be detected than in patients with lower triglycerides levels, whereas severe hypertriglyceridemia denotes a population with particularly increased mortality risk. (Circ Cardiovasc Qual Outcomes. 2016;9:100-108.
T he independent association between elevated triglyceride, cardiovascular risk, and mortality has long been controversial. 1, 2 Although the majority of studies have shown a significant association between elevated triglycerides with adverse outcomes, [3] [4] [5] [6] [7] [8] [9] [10] [11] this association sometimes became nonsignificant after multivariate adjustment including other lipid levels and weight-related variables. [12] [13] [14] [15] For example, in the largest meta-analysis to date, 12 triglycerides were shown to be independently associated with increased risk of coronary heart disease (CHD) after adjustment for age and sex, but this association became statistically nonsignificant after further adjustment for high-density lipoprotein (HDL)-cholesterol and non-HDL-C. As a result, the prognostic significance of hypertriglyceridemia and its role as a plausible therapeutic target is still a matter of active debates.
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Accordingly, we undertook the present study in an attempt to clarify the association between different triglyceride levels and long-term all-cause mortality (>22 years) in a large cohort of patients with proven CHD.
Methods

Study Population
was a secondary prevention prospective multicenter randomized, placebo-controlled, double-blinded trial (RCT) aimed to assess the efficacy of long-term administration of bezafibrate in reduction of coronary events. Screening and enrollment of patients were performed between February 1, 1990, and October 30, 1992 . Inclusion criteria for screening patients for the trial included the following: age 45 to 74 years, the history of a verified myocardial infarction (MI) 6 months to 5 years before inclusion, and stable angina pectoris with symptoms present during the 2 years preceding inclusion, or an objective documentation of related coronary artery disease, which was made by a positive exercise test, evidence of myocardial ischemia revealed by radionuclear studies, or angiographic evidence of at least 60% stenosis of 1 major coronary artery. 18 Exclusion criteria included diabetes mellitus requiring the use of insulin, severe heart failure, unstable angina, hepatic or renal failure, and current use of lipid-modifying drugs.
On the basis of these inclusion and exclusion criteria, the present study sample comprised 15 446 patients who were either screened for participation (12 324 patients) or eventually included in the BIP study (3122 patients). All study patients underwent a complete medical examination and biochemical blood tests; historical medical data and data on drug therapy were recorded. Median follow-up duration was 22.8 years.
The study was approved by the institute's internal review board and was performed according to the principles expressed in the Declaration of Helsinki and the ethics policy of the institute.
Laboratory Methods
Blood samples were drawn after at least 12 hours of fasting. Cooled samples, collected in the 18 participating centers using standard equipment and procedures, were transferred to the study's central laboratory. All analyses were performed on a Boehringer Hitachi 704 random access analyzer using Boehringer diagnostic kits. Detailed data on laboratory methods are given in a previous report. 19 Briefly, evaluation of triglycerides was performed by determination of total values (glycerol-3phosphate oxidase-phenol + aminophenazone high performance method) using a BM/Hitachi 717/911 analyzer. Glucose values were determined by the glucose oxidase-phenol + aminophenazone method. Cholesterol was determined by the cholesterol oxidase-phenol + aminophenazone method. The screening values obtained on the first visit were used for all the described analysis.
Classification of Triglycerides and Outcomes
The patients were divided into 5 groups according to strata of fasting serum triglycerides levels at screening. The categorization is based on the ATP III 4 triglyceride categories, 20 with further categorizing the normal triglyceride levels (<150 mg/dL) into low-normal and high-normal triglyceride levels. Accordingly, the 5 groups are (1) low-normal triglycerides (<100 mg/dL); (2) high-normal triglycerides (100-149 mg/dL); (3) borderline hypertriglyceridemia triglycerides (150-199 mg/dL); (4) moderate hypertriglyceridemia (200-499 mg/dL); (4) severe hypertriglyceridemia triglycerides (≥500 mg/dL). HDL-C was defined as low for values <40 mg/ dL for men and 50 mg/dL for women.
Mortality data were obtained by matching the patients' identification numbers with their vital status in the official National Population Registry. It should be stressed that each matched record was checked for correct identification by matching the study recorded date of birth, coded during enrollment, to the date of birth stored at the National registry. Patients with missing values or inconsistent matching were excluded from the analysis.
In addition, we matched patients' identification numbers with the National Cancer Registry to obtain data on incidental cancer during the time from enrollment. We used this data to perform a sensitivity analysis in which patients with incidental cancer were excluded.
Statistical Analysis
Variables were expressed as mean±SD, and categorical data were summarized as percentages. The clinical characteristics of the patients at baseline were compared among the subgroups, with the use of the Kruskal-Wallis test for continuous variables and the χ 2 test for dichotomous variables using Bonferroni adjusted P values for comparison. Spearman correlation was used to assess the relationship between HDL-C and APO B to triglycerides.
Survival analysis was performed using standardized Kaplan-Meier curves using the conditional approach balancing for sex and age confounders based on their distribution in our entire cohort as detailed by Therneau et al. 21 Multivariate analysis was performed using the Cox-proportional hazards regression method for the outcome of all-cause mortality. Several models were constructed by introducing prespecified covariates using the best-subset method. Because the distribution of triglyceride was skewed, a natural Log (Ln) of triglycerides was introduced into the model that assessed triglycerides as a continuous measure. The following models were prespecified: model 1-Ln triglycerides only; model 2-Ln triglycerides, age, and sex; model 3-Ln triglycerides, age, sex, and body mass index (BMI); model 4-Ln triglycerides, age, gender, BMI, low-density lipoprotein-cholesterol (LDL-C); model 5-Ln triglycerides, age, sex, BMI, LDL-C, and HDL-C; model 6-the fully adjusted Cox model included: age, sex, BMI, serum creatinine level, presence or absence of diabetes mellitus, chronic obstructive pulmonary disease, past MI, cerebrovascular accident, New York Heart Association functional class, systolic blood pressure, diagnosis of malignancy, heart failure, and serum concentrations of LDL-C and HDL-C. A separate analysis (model 7) was performed including only subjects enrolled in the BIP RCT after the screening phase (n=3122). Similarly, we explored the association of the different triglycerides groups against the group with
WHAT IS KNOWN
• Elevated triglyceride levels are associated with adverse outcome. • However, the independent association between elevated triglyceride and mortality is controversial.
WHAT THE STUDY ADDS
• In a large cohort of secondary prevention-eligible cardiac patients followed up for 22 years, elevated triglyceride levels are associated with an independent risk of death. • The association between elevated triglyceride levels and death is graded in a dose-response manner. • Even triglyceride levels of 100 to 149 mg/dL are associated with an increased risk of death.
triglycerides <100 mg/dL serving as the reference in a Cox model adjusted for age, diabetes mellitus, BMI, and HDL-C levels. Regression models goodness-of-fit was assessed by examination Schoenfeld and Cox-Snell residuals. A sensitivity analysis was performed using the fully adjusted model (model 6) after the exclusion of subjects that have been diagnosed with cancer during the 22-year follow-up period.
The association of hypertriglyceridemia (defined as triglycerides ≥200 mg/dL) was further explored among prespecified patients' subgroups by interaction term analysis. The following subgroups were explored: sex, low HDL-C levels (defined as <40 mg/dL for men and <50 mg/dL for women), diabetics, BMI (dichotomized at 30 kg/m 2 ), past and active smokers, fasting glucose levels dichotomized at 100 mg/dL, pervious MI, and inclusion in the BIP RCT. In addition to the interaction term triglycerides ≥200 mg/dL and the specific subgroup, the following covariates were included in the model: age, sex, serum creatinine level, presence or absence of diabetes mellitus, chronic obstructive pulmonary disease, past MI, cerebrovascular accident, New York Heart Association functional class, systolic blood pressure, and serum concentrations of LDL-C and HDL-C. The associated risk is graphically presented in form of a Forest plot.
All statistical tests were 2 sided, and a P value of <0.05 was considered statistically significant. The P values for interaction are reported. Analyses were performed with the use of SPSS software, version 22 (IBM Inc.), R statistical package (version 3.1), and SAS, version 9.3.
Results
Baseline Characteristics
Of the 15 446 patients available from the BIP study and screening registry, 91 subjects were excluded from the present Table 1 . Population comprised mostly of men (81%), aged 60±7 years, the majority having a history of a previous MI (72%).
Patients in the higher triglycerides groups were significantly younger but presented with a higher BMI, and greater prevalence of diabetes mellitus and active smoking. Consistently, HDL-C and APO B levels were inversely and directly correlated, with increasing levels of triglycerides (correlation coefficients, −0.41 and 0.20, respectively; both P<0.01). Comorbidities such as peripheral vascular disease, chronic obstructive lung disease, and past cerebrovascular accident or transient ischemic attack, as well as number of pervious MI events did not differ significantly among groups. Patients with greater triglycerides levels were more likely to be classified as New York Heart Association functional class >1 (Table 1) . Although, some differences exist in the baseline medication levels, the majority received no lipid-modifying medication (>90%).
Long-Term Outcomes
Age-and sex-adjusted survival differed significantly among triglycerides groups: it was 41% in the low-normal triglycerides group (<100 mg/dL) than 37%, 36%, 35%, and 25% in groups with progressively higher concentrations of triglycerides (100-149, 150-199, 200-499, ≥500 mg/dL, respectively; log-rank P<0.001; Figure 1 ).
Multivariate Cox-proportional hazards regression modeling (after adjustment for age, HDL-C, BMI, and presence of diabetes mellitus; Figure 2 ; Table I in the Data Supplement) showed that triglycerides groups 150-200, 200-499, and ≥500 mg/dL were associated, respectively, with 16%, 29%, and 68% increased mortality risk when compared with the group with triglycerides values <100 mg/dL (serving as the reference group). Notably, there was a marginally increased risk mortality risk among triglycerides group 100 to 150 mg/dL (hazard ratio [HR], 1.06; confidence interval [CI], 1.01-1.12).
When triglycerides were assessed as a continuous measure (normalized because of skewed distribution as Ln triglycerides), each unit increment in Ln triglycerides was shown to be independently associated with 26% greater mortality risk when adjusted for age and sex only (Table 2, model 2). This association remained statistically significant (HR, 1.12; CI, 1.06-1.18) after the introduction of HDL-C level into the model (model 5). In a Cox-regression fully adjusted model (Table 2, model 6; Table II in the Data Supplement), each 1 unit of Ln triglycerides elevation was associated with a marginally increased risk of all-cause mortality (HR, 1.06; CI, 1.01-1.12). Consistent results were obtained when subjects participating in the BIP RCT (n=3122) were separately analyzed (Table 2, model 7). A sensitivity analysis showed consistent results after excluding patients who developed incidental cancer during follow-up (n=3933; 25.4% of entire cohort).
Subgroup Analysis
The age-adjusted effect of moderate and severe hypertriglyceridemia, defined as triglycerides ≥200 mg/dL was consistent across the prespecified patient subgroups including diabetes mellitus, low HDL-C levels, high BMI, and smoking. Subgroup analysis is presented in Figure 3 . Thus, elevated triglycerides were similarly associated with mortality in all analyzed subsets, with the exception of the relatively small group of female patients (n=2962; 19% of all study population).
Discussion
Our study, performed in a large cohort of secondary prevention-eligible cardiac patients, who were followed up >22 years for fatal events, has several important clinical implications: (1) elevated triglycerides level is associated with increased long-term mortality in patients with established CHD even after full adjustment including HDL-C. This effect is graded: the higher the triglycerides concentration the higher the independent mortality risk; (2) even triglycerides levels of 100 to 149 mg/dL are associated with a small increased risk for all cause-mortality; (3) Severe hypertriglyceridemia (triglycerides >500 mg/dL) denotes a population at substantially greater mortality risk. To our knowledge, the present study represents the largest reported study with the longest follow-up period, which explores the relationship between triglycerides levels and mortality in patients with established CHD.
Comparison With Other Studies
Most previous studies have evaluated the role of triglycerides in subjects free of CHD. The data on subjects with established CHD are limited only to many small studies with relatively short follow-up periods, which have shown inconclusive results. [22] [23] [24] For example, in a study by Cheng et al 22 on 247 patients with ST-segment-elevation MI who were treated with primary PCI and followed up for a period of 1.23 to 1.4 years, higher levels of triglycerides (>150 versus <150 mg/dL) were paradoxically associated with a lower rate of overall major adverse cardiac events. This discrepancy could be explained by different study populations (acute versus stable CHD patients), different outcome measures, and chance, reflecting a post hoc finding. Yun et al 24 showed in 325 patients who underwent PCI and received statins, that high triglycerides levels (>150 mg/ dL), 4 weeks after PCI, are an independent predictor of major adverse cardiac events (HR, 4.01; CI, 1.85-9.06). Similar to our results, results by Sprecher et al 23 showed that after coronary artery bypass grafting, triglycerides levels are predictive of long-term all-cause mortality risk (mostly 5-year mortality), yet the results were not fully adjusted for HDL-C.
Kasai et al 25 demonstrated in a study of 1836 patients after complete revascularization that triglycerides levels are independently associated with increased risk of cardiac death but not with all-cause mortality, or was there a significant adjusted association with cardiovascular mortality in the patient group with triglycerides ranging from 100 to 200 mg/dL. In a previous analysis from the BIP Registry including 11 532 patients 26 with a shorter follow-up period, there was a stepwise increase in age-adjusted 5-year mortality with increasing triglyceride levels, yet after adjustment for HDL-C and other covariates, this association failed to reach statistical significance. In the current study, we included 15 355 patients with considerably longer follow-up period and have shown that elevated triglycerides levels are associated with increased risk for 22-year mortality (HR, 1.06; CI, 1.01-1.12), and the results are consistent in all subgroup tested after adjustment for multiple covariates including HDL-C. Our study encompassed markedly greater number of end point events and thus had greater statistical power than previous studies from the BIP registry and trial. The risk associated with hypertriglyceridemia is attenuated after adjustment for medical history, laboratory values, and risk factors, probably denoting the complex association where triglycerides exerts both direct biological effects, yet also serve as a marker for more severe metabolic abnormalities, comorbidities, and cardiovascular disease. 
Threshold for Elevated Triglycerides Level
Classification of serum triglyceride levels >150 mg/dL (1.7 mmol/L) as elevated is mainly based on large prospective observational studies. However, the exact level at which serum triglycerides start to confer risk is unknown. 27 The triglycerides classification cut points have been lowered over the years. 21 Previous reports have shown an excessive risk for cardiovascular disease even among subjects with triglycerides levels within the so-called normal range. 9 Epidemiological data taken together raise the possibility that an optimal fasting triglyceride level might be <100 mg/dL. However, to the best of our knowledge, there were no published reports on the relationship between low-and highnormal levels of triglycerides and long-term mortality in populations with established CHD. We demonstrated that even triglyceride levels between 100 and 149 mg/dL (versus triglycerides <100 mg/dL) were associated with excessive risk of 22-year all-cause mortality, yet this association is marginally significant and therefore warrants further validation.
Pendulum Moves From HDL-C to Triglycerides
High-density lipoprotein and triglycerides tend to vary inversely. Traditional thought has focused on the benefits of raising HDL-C as a protective factor against atherosclerosis. The inverse association between HDL-C and triglycerides complicates analysis designed to evaluate the independent contribution of elevated triglycerides levels to mortality. Although the majority of studies found a substantial direct association between triglycerides and adverse outcomes, [3] [4] [5] [6] [7] [8] [9] [10] [11] 28, 29 triglycerides have received less attention as a causal risk factor, as adjustment for HDL-C and other potential cofounders, tend to attenuate or nullify the association between triglycerides concentration and cardiovascular risk. [12] [13] [14] [15] 30, 31 In a recent longitudinal observational study in out-patients with type 2 diabetes mellitus, mean triglycerides levels were significantly associated with all-cause mortality after adjustment for several confounding factors including mean values of HDL-C. 32 In our report, triglycerides levels are significantly associated with excessive risk for 22-year mortality, even after adjustment for HDL-C and for other potential confounders. It is noteworthy that the associated risk is attenuated after adjustment for other risk factors and comorbidities, possibly denoting the complex association between triglycerides levels and mortality, where elevated triglycerides exert both a direct biological effect and also represent a marker of more advanced atherosclerosis.
Multiple strategies to raise HDL-C levels as a primary goal have failed to date to show clinical benefit. Moreover, recent genetic studies have also cast doubt on HDL-C as a causal risk factor. 33 There is a growing evidence suggesting a causal role between triglycerides and cardiovascular risk and that treating high triglycerides levels in addition to treating high LDL-C may be beneficial. 34 Contemporary genetic analyses indicate that higher concentration of triglycerides contributes directly to the pathogenesis of ischemic heart disease. 35 Elevated apolipoprotein C3, a protein associates with triglyceride-rich lipoproteins, is associated with greater cardiovascular risk. 36 Two recently published independent large studies provide strong evidence for the causal role of apolipoprotein C3 and triglycerides in atherosclerotic vascular disease. 37, 38 The results published in our report support the renewed interest in triglycerides as a possible therapeutic target for cardiovascular risk reduction. An interesting lesson could be derived from the BIP study: despite of a significant HDL-C increase in the bezafibrate treatment arm, the overall benefits were nonsignificant. However, the benefit of bezafibrate in the subgroup of patients with high triglycerides levels was impressive. 39 In all the available 5 randomized control trials, the beneficial effects of fibrates were highly significant in patients with hypertriglyceridemia. [39] [40] [41] [42] [43] [44] 
Limitations
Our study presents many limitations. First, we have limited follow-up data of patients after screening visits (registry group) or after the RCT BIP study completion (randomized study group). Thus, we could not adjust for potentially confounders, such as morbidity and treatment given, during the entire follow-up period. Second, we do not have information on the cause of death. However, even after excluding patients with incidental cancer, higher triglycerides levels remained independently associated with increased all-cause mortality. In addition, some indirect estimation could be partially derived from the experience with 3122 patients enrolled in the BIP RCT. Their data have shown that after 8 years of followup, ≈58% of deaths were because of a cardiovascular cause (similarly in both study arms). 45 Therefore, our assumption that the major reason for triglyceride-associated increased mortality is cardiovascular disease seems logical.
Third, diabetes mellitus status was based on medical records obtained at baseline for all participants. This fact can cause a misclassification of diabetes mellitus and potentially can lead to bias toward higher risk in the higher triglycerides groups. However, our fully multivariate adjusted model, included adjustment for baseline glucose level >100 mg/dL. Thus, it lessens the impact of a potential misclassification of diabetes mellitus status.
Fourth, our analysis is based on a single measurement of fasting triglyceride levels and cannot adjust for possible variations over time. Another important limitation of our report is related to the lack of racial/ethnic diversity in patients who participated in the BIP registry. This limits the generalizability of our results. Moreover, the BIP study and registry enrolled mostly men; thus, women were under-represented. Probably because of a small sample size, the current analysis failed to demonstrate a statistically significant triglyceride-associated mortality risk in women.
The lack of clinical and laboratory data during the followup period may also limits the interpretation of the results given the inability to adjust for confounders occurring during follow-up (ie, changes in management strategies since the early 1980s, variations in the triglycerides levels in each triglycerides group, and the possible effect of development of time-dependent cardiovascular risk factors or diabetes mellitus on subsequently mortality).
Conclusions
Elevated triglycerides in patients with established CHD are associated with a long-term mortality risk that is independent of HDL-C levels. Even among subjects with triglycerides >100 mg/dL, the higher mortality risk could be detected. Severe hypertriglyceridemia (triglycerides >500 mg/dL) denotes a population with particularly increased mortality risk. The current threshold for the definition of elevated triglycerides level for patients with CHD may be higher than desired. Prospective studies in appropriately selected subjects should further clarify these important aspects.
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